Global Immune Checkpoint Inhibitors
Global Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors Comprehensive Study by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Application (Melanoma, Lung Cancer, Urothelial Carcinoma, Hodgkin Lymphoma, Squamous Cell Carcinoma, Blood Cancer, Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Immune Checkpoint Inhibitors Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 220 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Immune Checkpoint Inhibitors Market Scope
Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells. Checkpoint Inhibitors help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better. The immune Checkpoint Inhibitors market is expected to grow in the future due to technological advancements in screening procedures for cancer and increased healthcare expenditures in developing countries. Increase in government initiatives to alleviate cancer future boosting the market in forecasted period.

The Immune Checkpoint Inhibitors market study is segmented by Type (CTLA-4 Inhibitor, PD-1 Inhibitor and PD-L1 Inhibitor), by Application (Melanoma, Lung Cancer, Urothelial Carcinoma, Hodgkin Lymphoma, Squamous Cell Carcinoma, Blood Cancer and Others) and major geographies with country level break-up.

Market players are focusing on partnerships, collaborations, and new product launches in order to increase their offerings in the synthetic fibers market. In addition, companies are focusing on increasing their client base to strengthen their market position and to enhance product offerings. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Immune Checkpoint Inhibitors market throughout the predicted period.

Bristol Myer Squibb (United States), AstraZeneca plc (United Kingdom), Merck & Co. (United States), F. Hoffmann-La Roche AG (Switzerland), Incyte Corporation (United States), NewLink Genetics (United States), ArGEN-X (Netherlands), Seagen Inc. (United States), Pfizer Inc. (United States), MacroGenics (United States), Celldex Therapeutics (United States), Immutep Ltd (Australia) and Innate Pharma (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sorrento Therapeutics (United States), GlaxoSmithKline (United Kingdom) and GITR, Inc (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Immune Checkpoint Inhibitors market by Type, Application and Region.

On the basis of geography, the market of Immune Checkpoint Inhibitors has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Oct.2020, CStone Pharmaceuticals announced an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications.
In Jun 2019, Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.


Market Trend
  • Technological Advancements in Screening Procedure for Cancer

Market Drivers
  • Rising Prevalence of Cancer-related Disorders Worldwide
  • Adoption of an Unhealthy Lifestyle and Genetic Modification/Alteration

Opportunities
  • Surge in Healthcare Expenditures in Developing Countries
  • Increase in Government Initiatives to Alleviate Cancer

Restraints
  • Side Effect after the Treatment

Challenges
  • Stringent FDA Guidelines for the Drug Approval of New Drug


Key Target Audience
Immune Checkpoint Inhibitors Providers, Government and Private Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor
By Application
  • Melanoma
  • Lung Cancer
  • Urothelial Carcinoma
  • Hodgkin Lymphoma
  • Squamous Cell Carcinoma
  • Blood Cancer
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others

By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer-related Disorders Worldwide
      • 3.2.2. Adoption of an Unhealthy Lifestyle and Genetic Modification/Alteration
    • 3.3. Market Challenges
      • 3.3.1. Stringent FDA Guidelines for the Drug Approval of New Drug
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Screening Procedure for Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immune Checkpoint Inhibitors, by Type, Application, Route of Administration, Distribution Channel, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Immune Checkpoint Inhibitors (Value)
      • 5.2.1. Global Immune Checkpoint Inhibitors by: Type (Value)
        • 5.2.1.1. CTLA-4 Inhibitor
        • 5.2.1.2. PD-1 Inhibitor
        • 5.2.1.3. PD-L1 Inhibitor
      • 5.2.2. Global Immune Checkpoint Inhibitors by: Application (Value)
        • 5.2.2.1. Melanoma
        • 5.2.2.2. Lung Cancer
        • 5.2.2.3. Urothelial Carcinoma
        • 5.2.2.4. Hodgkin Lymphoma
        • 5.2.2.5. Squamous Cell Carcinoma
        • 5.2.2.6. Blood Cancer
        • 5.2.2.7. Others
      • 5.2.3. Global Immune Checkpoint Inhibitors by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
        • 5.2.3.3. Others
      • 5.2.4. Global Immune Checkpoint Inhibitors by: Distribution Channel (Value)
        • 5.2.4.1. Retail Pharmacies
        • 5.2.4.2. Hospital Pharmacies
      • 5.2.5. Global Immune Checkpoint Inhibitors by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Specialty Clinics
        • 5.2.5.3. Others
      • 5.2.6. Global Immune Checkpoint Inhibitors Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Immune Checkpoint Inhibitors (Price)
      • 5.3.1. Global Immune Checkpoint Inhibitors by: Type (Price)
  • 6. Immune Checkpoint Inhibitors: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol Myer Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Incyte Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NewLink Genetics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ArGEN-X (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Seagen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MacroGenics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Celldex Therapeutics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Immutep Ltd (Australia)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Innate Pharma (France)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Immune Checkpoint Inhibitors Sale, by Type, Application, Route of Administration, Distribution Channel, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Immune Checkpoint Inhibitors (Value)
      • 7.2.1. Global Immune Checkpoint Inhibitors by: Type (Value)
        • 7.2.1.1. CTLA-4 Inhibitor
        • 7.2.1.2. PD-1 Inhibitor
        • 7.2.1.3. PD-L1 Inhibitor
      • 7.2.2. Global Immune Checkpoint Inhibitors by: Application (Value)
        • 7.2.2.1. Melanoma
        • 7.2.2.2. Lung Cancer
        • 7.2.2.3. Urothelial Carcinoma
        • 7.2.2.4. Hodgkin Lymphoma
        • 7.2.2.5. Squamous Cell Carcinoma
        • 7.2.2.6. Blood Cancer
        • 7.2.2.7. Others
      • 7.2.3. Global Immune Checkpoint Inhibitors by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
        • 7.2.3.3. Others
      • 7.2.4. Global Immune Checkpoint Inhibitors by: Distribution Channel (Value)
        • 7.2.4.1. Retail Pharmacies
        • 7.2.4.2. Hospital Pharmacies
      • 7.2.5. Global Immune Checkpoint Inhibitors by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Specialty Clinics
        • 7.2.5.3. Others
      • 7.2.6. Global Immune Checkpoint Inhibitors Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Immune Checkpoint Inhibitors (Price)
      • 7.3.1. Global Immune Checkpoint Inhibitors by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immune Checkpoint Inhibitors: by Type(USD Million)
  • Table 2. Immune Checkpoint Inhibitors CTLA-4 Inhibitor , by Region USD Million (2015-2020)
  • Table 3. Immune Checkpoint Inhibitors PD-1 Inhibitor , by Region USD Million (2015-2020)
  • Table 4. Immune Checkpoint Inhibitors PD-L1 Inhibitor , by Region USD Million (2015-2020)
  • Table 5. Immune Checkpoint Inhibitors: by Application(USD Million)
  • Table 6. Immune Checkpoint Inhibitors Melanoma , by Region USD Million (2015-2020)
  • Table 7. Immune Checkpoint Inhibitors Lung Cancer , by Region USD Million (2015-2020)
  • Table 8. Immune Checkpoint Inhibitors Urothelial Carcinoma , by Region USD Million (2015-2020)
  • Table 9. Immune Checkpoint Inhibitors Hodgkin Lymphoma , by Region USD Million (2015-2020)
  • Table 10. Immune Checkpoint Inhibitors Squamous Cell Carcinoma , by Region USD Million (2015-2020)
  • Table 11. Immune Checkpoint Inhibitors Blood Cancer , by Region USD Million (2015-2020)
  • Table 12. Immune Checkpoint Inhibitors Others , by Region USD Million (2015-2020)
  • Table 13. Immune Checkpoint Inhibitors: by Route of Administration(USD Million)
  • Table 14. Immune Checkpoint Inhibitors Oral , by Region USD Million (2015-2020)
  • Table 15. Immune Checkpoint Inhibitors Parenteral , by Region USD Million (2015-2020)
  • Table 16. Immune Checkpoint Inhibitors Others , by Region USD Million (2015-2020)
  • Table 17. Immune Checkpoint Inhibitors: by Distribution Channel(USD Million)
  • Table 18. Immune Checkpoint Inhibitors Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 19. Immune Checkpoint Inhibitors Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 20. Immune Checkpoint Inhibitors: by End User(USD Million)
  • Table 21. Immune Checkpoint Inhibitors Hospitals , by Region USD Million (2015-2020)
  • Table 22. Immune Checkpoint Inhibitors Specialty Clinics , by Region USD Million (2015-2020)
  • Table 23. Immune Checkpoint Inhibitors Others , by Region USD Million (2015-2020)
  • Table 24. South America Immune Checkpoint Inhibitors, by Country USD Million (2015-2020)
  • Table 25. South America Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 26. South America Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 27. South America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 28. South America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 29. South America Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 30. Brazil Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 31. Brazil Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 32. Brazil Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 33. Brazil Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 34. Brazil Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 35. Argentina Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 36. Argentina Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 37. Argentina Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 38. Argentina Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 39. Argentina Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 40. Rest of South America Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 41. Rest of South America Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 42. Rest of South America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 43. Rest of South America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 44. Rest of South America Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 45. Asia Pacific Immune Checkpoint Inhibitors, by Country USD Million (2015-2020)
  • Table 46. Asia Pacific Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 47. Asia Pacific Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 48. Asia Pacific Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 49. Asia Pacific Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 50. Asia Pacific Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 51. China Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 52. China Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 53. China Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 54. China Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 55. China Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 56. Japan Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 57. Japan Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 58. Japan Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 59. Japan Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 60. Japan Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 61. India Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 62. India Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 63. India Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 64. India Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 65. India Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 66. South Korea Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 67. South Korea Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 68. South Korea Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 69. South Korea Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 70. South Korea Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 71. Taiwan Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 72. Taiwan Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 73. Taiwan Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 74. Taiwan Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 75. Taiwan Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 76. Australia Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 77. Australia Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 78. Australia Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 79. Australia Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 80. Australia Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 86. Europe Immune Checkpoint Inhibitors, by Country USD Million (2015-2020)
  • Table 87. Europe Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 88. Europe Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 89. Europe Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 90. Europe Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 91. Europe Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 92. Germany Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 93. Germany Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 94. Germany Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 95. Germany Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 96. Germany Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 97. France Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 98. France Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 99. France Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 100. France Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 101. France Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 102. Italy Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 103. Italy Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 104. Italy Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 105. Italy Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 106. Italy Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 107. United Kingdom Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 108. United Kingdom Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 109. United Kingdom Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 110. United Kingdom Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 111. United Kingdom Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 112. Netherlands Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 113. Netherlands Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 114. Netherlands Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 115. Netherlands Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 116. Netherlands Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 117. Rest of Europe Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 118. Rest of Europe Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 119. Rest of Europe Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 120. Rest of Europe Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 121. Rest of Europe Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 122. MEA Immune Checkpoint Inhibitors, by Country USD Million (2015-2020)
  • Table 123. MEA Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 124. MEA Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 125. MEA Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 126. MEA Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 127. MEA Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 128. Middle East Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 129. Middle East Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 130. Middle East Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 131. Middle East Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 132. Middle East Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 133. Africa Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 134. Africa Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 135. Africa Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 136. Africa Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 137. Africa Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 138. North America Immune Checkpoint Inhibitors, by Country USD Million (2015-2020)
  • Table 139. North America Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 140. North America Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 141. North America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 142. North America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 143. North America Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 144. United States Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 145. United States Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 146. United States Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 147. United States Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 148. United States Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 149. Canada Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 150. Canada Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 151. Canada Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 152. Canada Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 153. Canada Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 154. Mexico Immune Checkpoint Inhibitors, by Type USD Million (2015-2020)
  • Table 155. Mexico Immune Checkpoint Inhibitors, by Application USD Million (2015-2020)
  • Table 156. Mexico Immune Checkpoint Inhibitors, by Route of Administration USD Million (2015-2020)
  • Table 157. Mexico Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2015-2020)
  • Table 158. Mexico Immune Checkpoint Inhibitors, by End User USD Million (2015-2020)
  • Table 159. Immune Checkpoint Inhibitors: by Type(USD/Units)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Immune Checkpoint Inhibitors: by Type(USD Million)
  • Table 174. Immune Checkpoint Inhibitors CTLA-4 Inhibitor , by Region USD Million (2021-2026)
  • Table 175. Immune Checkpoint Inhibitors PD-1 Inhibitor , by Region USD Million (2021-2026)
  • Table 176. Immune Checkpoint Inhibitors PD-L1 Inhibitor , by Region USD Million (2021-2026)
  • Table 177. Immune Checkpoint Inhibitors: by Application(USD Million)
  • Table 178. Immune Checkpoint Inhibitors Melanoma , by Region USD Million (2021-2026)
  • Table 179. Immune Checkpoint Inhibitors Lung Cancer , by Region USD Million (2021-2026)
  • Table 180. Immune Checkpoint Inhibitors Urothelial Carcinoma , by Region USD Million (2021-2026)
  • Table 181. Immune Checkpoint Inhibitors Hodgkin Lymphoma , by Region USD Million (2021-2026)
  • Table 182. Immune Checkpoint Inhibitors Squamous Cell Carcinoma , by Region USD Million (2021-2026)
  • Table 183. Immune Checkpoint Inhibitors Blood Cancer , by Region USD Million (2021-2026)
  • Table 184. Immune Checkpoint Inhibitors Others , by Region USD Million (2021-2026)
  • Table 185. Immune Checkpoint Inhibitors: by Route of Administration(USD Million)
  • Table 186. Immune Checkpoint Inhibitors Oral , by Region USD Million (2021-2026)
  • Table 187. Immune Checkpoint Inhibitors Parenteral , by Region USD Million (2021-2026)
  • Table 188. Immune Checkpoint Inhibitors Others , by Region USD Million (2021-2026)
  • Table 189. Immune Checkpoint Inhibitors: by Distribution Channel(USD Million)
  • Table 190. Immune Checkpoint Inhibitors Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 191. Immune Checkpoint Inhibitors Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 192. Immune Checkpoint Inhibitors: by End User(USD Million)
  • Table 193. Immune Checkpoint Inhibitors Hospitals , by Region USD Million (2021-2026)
  • Table 194. Immune Checkpoint Inhibitors Specialty Clinics , by Region USD Million (2021-2026)
  • Table 195. Immune Checkpoint Inhibitors Others , by Region USD Million (2021-2026)
  • Table 196. South America Immune Checkpoint Inhibitors, by Country USD Million (2021-2026)
  • Table 197. South America Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 198. South America Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 199. South America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 200. South America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 201. South America Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 202. Brazil Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 203. Brazil Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 204. Brazil Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 205. Brazil Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 206. Brazil Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 207. Argentina Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 208. Argentina Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 209. Argentina Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 210. Argentina Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 211. Argentina Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 212. Rest of South America Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 213. Rest of South America Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 214. Rest of South America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 215. Rest of South America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 216. Rest of South America Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 217. Asia Pacific Immune Checkpoint Inhibitors, by Country USD Million (2021-2026)
  • Table 218. Asia Pacific Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 219. Asia Pacific Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 220. Asia Pacific Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 221. Asia Pacific Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 222. Asia Pacific Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 223. China Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 224. China Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 225. China Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 226. China Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 227. China Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 228. Japan Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 229. Japan Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 230. Japan Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 231. Japan Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 232. Japan Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 233. India Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 234. India Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 235. India Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 236. India Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 237. India Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 238. South Korea Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 239. South Korea Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 240. South Korea Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 241. South Korea Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 242. South Korea Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 243. Taiwan Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 244. Taiwan Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 245. Taiwan Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 246. Taiwan Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 247. Taiwan Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 248. Australia Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 249. Australia Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 250. Australia Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 251. Australia Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 252. Australia Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 256. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 257. Rest of Asia-Pacific Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 258. Europe Immune Checkpoint Inhibitors, by Country USD Million (2021-2026)
  • Table 259. Europe Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 260. Europe Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 261. Europe Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 262. Europe Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 263. Europe Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 264. Germany Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 265. Germany Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 266. Germany Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 267. Germany Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 268. Germany Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 269. France Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 270. France Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 271. France Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 272. France Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 273. France Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 274. Italy Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 275. Italy Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 276. Italy Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 277. Italy Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 278. Italy Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 279. United Kingdom Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 280. United Kingdom Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 281. United Kingdom Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 282. United Kingdom Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 283. United Kingdom Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 284. Netherlands Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 285. Netherlands Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 286. Netherlands Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 287. Netherlands Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 288. Netherlands Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 289. Rest of Europe Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 290. Rest of Europe Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 291. Rest of Europe Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 292. Rest of Europe Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 293. Rest of Europe Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 294. MEA Immune Checkpoint Inhibitors, by Country USD Million (2021-2026)
  • Table 295. MEA Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 296. MEA Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 297. MEA Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 298. MEA Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 299. MEA Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 300. Middle East Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 301. Middle East Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 302. Middle East Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 303. Middle East Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 304. Middle East Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 305. Africa Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 306. Africa Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 307. Africa Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 308. Africa Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 309. Africa Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 310. North America Immune Checkpoint Inhibitors, by Country USD Million (2021-2026)
  • Table 311. North America Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 312. North America Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 313. North America Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 314. North America Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 315. North America Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 316. United States Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 317. United States Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 318. United States Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 319. United States Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 320. United States Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 321. Canada Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 322. Canada Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 323. Canada Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 324. Canada Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 325. Canada Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 326. Mexico Immune Checkpoint Inhibitors, by Type USD Million (2021-2026)
  • Table 327. Mexico Immune Checkpoint Inhibitors, by Application USD Million (2021-2026)
  • Table 328. Mexico Immune Checkpoint Inhibitors, by Route of Administration USD Million (2021-2026)
  • Table 329. Mexico Immune Checkpoint Inhibitors, by Distribution Channel USD Million (2021-2026)
  • Table 330. Mexico Immune Checkpoint Inhibitors, by End User USD Million (2021-2026)
  • Table 331. Immune Checkpoint Inhibitors: by Type(USD/Units)
  • Table 332. Research Programs/Design for This Report
  • Table 333. Key Data Information from Secondary Sources
  • Table 334. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immune Checkpoint Inhibitors: by Type USD Million (2015-2020)
  • Figure 5. Global Immune Checkpoint Inhibitors: by Application USD Million (2015-2020)
  • Figure 6. Global Immune Checkpoint Inhibitors: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Immune Checkpoint Inhibitors: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Immune Checkpoint Inhibitors: by End User USD Million (2015-2020)
  • Figure 9. South America Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 10. Asia Pacific Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 11. Europe Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 12. MEA Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 13. North America Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 14. Global Immune Checkpoint Inhibitors: by Type USD/Units (2015-2020)
  • Figure 15. Global Immune Checkpoint Inhibitors share by Players 2020 (%)
  • Figure 16. Global Immune Checkpoint Inhibitors share by Players (Top 3) 2020(%)
  • Figure 17. Global Immune Checkpoint Inhibitors share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Bristol Myer Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol Myer Squibb (United States) Revenue: by Geography 2020
  • Figure 21. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 25. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Incyte Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Incyte Corporation (United States) Revenue: by Geography 2020
  • Figure 29. NewLink Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 30. NewLink Genetics (United States) Revenue: by Geography 2020
  • Figure 31. ArGEN-X (Netherlands) Revenue, Net Income and Gross profit
  • Figure 32. ArGEN-X (Netherlands) Revenue: by Geography 2020
  • Figure 33. Seagen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Seagen Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 37. MacroGenics (United States) Revenue, Net Income and Gross profit
  • Figure 38. MacroGenics (United States) Revenue: by Geography 2020
  • Figure 39. Celldex Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 40. Celldex Therapeutics (United States) Revenue: by Geography 2020
  • Figure 41. Immutep Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 42. Immutep Ltd (Australia) Revenue: by Geography 2020
  • Figure 43. Innate Pharma (France) Revenue, Net Income and Gross profit
  • Figure 44. Innate Pharma (France) Revenue: by Geography 2020
  • Figure 45. Global Immune Checkpoint Inhibitors: by Type USD Million (2021-2026)
  • Figure 46. Global Immune Checkpoint Inhibitors: by Application USD Million (2021-2026)
  • Figure 47. Global Immune Checkpoint Inhibitors: by Route of Administration USD Million (2021-2026)
  • Figure 48. Global Immune Checkpoint Inhibitors: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Immune Checkpoint Inhibitors: by End User USD Million (2021-2026)
  • Figure 50. South America Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 51. Asia Pacific Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 52. Europe Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 53. MEA Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 54. North America Immune Checkpoint Inhibitors Share (%), by Country
  • Figure 55. Global Immune Checkpoint Inhibitors: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Bristol Myer Squibb (United States)
  • AstraZeneca plc (United Kingdom)
  • Merck & Co. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Incyte Corporation (United States)
  • NewLink Genetics (United States)
  • ArGEN-X (Netherlands)
  • Seagen Inc. (United States)
  • Pfizer Inc. (United States)
  • MacroGenics (United States)
  • Celldex Therapeutics (United States)
  • Immutep Ltd (Australia)
  • Innate Pharma (France)
Additional players considered in the study are as follows:
Sorrento Therapeutics (United States) , GlaxoSmithKline (United Kingdom) , GITR, Inc (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation